Table 4.

Two-year overall survival and response rate of 151 patients with MDS, sAML, and de novo AML treated with azacitidine ± DLI for relapse after allo-HSCT according to the proposed scoring system.

Risk Score/Group	Response Rate (CR) after Azacitidine	2-y OS Rate after Azacitidine [±SEM]
1 (n = 28)	71%	64% ± 11%
2 (n = 64)	39%	38% ± 8%
3 (n = 59)	29%	27% ± 7%
	p = 0.0007	p = 0.0012

Note: allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; BM, bone marrow; CR, complete remission; DLI, donor lymphocyte infusion; MDS, myelodysplastic syndrome; OS, overall survival; sAML, secondary AML; SEM, standard error of the mean; y, year.